<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03801473</url>
  </required_header>
  <id_info>
    <org_study_id>Tugba Ozsoy</org_study_id>
    <nct_id>NCT03801473</nct_id>
  </id_info>
  <brief_title>Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients</brief_title>
  <official_title>Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare conventional neurorehabilitation with robot-assisted gait
      training program in terms of fatigue, anxiety, depression and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gait disturbances are common in Multiple Sclerosis (MS) patients. Nowadays, gait training
      with robot assisted technology is used for rehabilitation. In several studies conventional
      rehabilitation was compared with robot assisted rehabilitation program, and they found no
      superior effects of robot assisted walking program. In this study we aimed to compare these
      modalities in terms of fatigue, anxiety and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Initial assessments will be performed by first clinician (EA). Then, patients will be randomly grouped. The outcome assessor, second clinician (TOU) will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>fatigue severity score</measure>
    <time_frame>baseline</time_frame>
    <description>Patient-reported outcome measure which is composed of 9 items and evaluates the severity of fatigue. The items are scored on a 7-point scale with 1=strongly disagree and 7=strongly agree. The minimum score is 9 and maximum possible score is 63. Higher score reflects greater fatigue severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fatigue severity score</measure>
    <time_frame>after treatment (4th week)</time_frame>
    <description>Patient-reported outcome measure which is composed of 9 items and evaluates the severity of fatigue. The items are scored on a 7-point scale with 1=strongly disagree and 7=strongly agree. The minimum score is 9 and maximum possible score is 63. Higher score reflects greater fatigue severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fatigue severity score</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Patient-reported outcome measure which is composed of 9 items and evaluates the severity of fatigue. The items are scored on a 7-point scale with 1=strongly disagree and 7=strongly agree. The minimum score is 9 and maximum possible score is 63. Higher score reflects greater fatigue severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>walking ability</measure>
    <time_frame>baseline</time_frame>
    <description>The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>walking ability</measure>
    <time_frame>after treatment (4th week)</time_frame>
    <description>The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>walking ability</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>baseline</time_frame>
    <description>The EDSS assesses the disability status of MS patients on a scale range from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>after treatment (4th week)</time_frame>
    <description>The EDSS assesses the disability status of MS patients on a scale range from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>The EDSS assesses the disability status of MS patients on a scale range from 0 to 10 in 0.5 unit increments that represent higher levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ambulation Classification</measure>
    <time_frame>baseline</time_frame>
    <description>scored 1 to 6 (non functional ambulator to independant ambulator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ambulation Classification</measure>
    <time_frame>after treatment (4th week)</time_frame>
    <description>scored 1 to 6 (non functional ambulator to independant ambulator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ambulation Classification</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>scored 1 to 6 (non functional ambulator to independant ambulator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Quality of Life-54 (MSQOL-54)</measure>
    <time_frame>baseline</time_frame>
    <description>The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items. This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. The subscales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The summary scores are the physical health composite summary and the mental health composite summary. The single item measures are satisfaction with sexual function and change in health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Quality of Life-54 (MSQOL-54)</measure>
    <time_frame>after treatment (4th week)</time_frame>
    <description>The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items. This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. The subscales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The summary scores are the physical health composite summary and the mental health composite summary. The single item measures are satisfaction with sexual function and change in health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Quality of Life-54 (MSQOL-54)</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>The MSQOL-54 is a multidimensional health-related quality of life measure that combines both generic and MS-specific items. This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. The subscales are: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The summary scores are the physical health composite summary and the mental health composite summary. The single item measures are satisfaction with sexual function and change in health.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>robot assisted gait</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>robot assisted gait therapy</intervention_name>
    <description>The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.</description>
    <arm_group_label>robot assisted gait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional rehabilitation</intervention_name>
    <description>Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.</description>
    <arm_group_label>conventional rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years old Multiple Sclerosis patients

          -  EDSS score: 5.5-7.5

          -  Being oriented and cooperated

          -  Mini-mental score â‰¥24/30

        Exclusion Criteria:

          -  Modified Ashworth &gt;3 in lower extremity muscles

          -  Cognitive impairment

          -  Botox injection within last 6-months

          -  Having another neurological disease

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sultan Abdulhamid Han Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tugba Ozsoy-Unubol</last_name>
      <phone>+902165422020</phone>
      <phone_ext>3857</phone_ext>
      <email>tugbaozsoyy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Lefeber N, Swinnen E, Kerckhofs E. The immediate effects of robot-assistance on energy consumption and cardiorespiratory load during walking compared to walking without robot-assistance: a systematic review. Disabil Rehabil Assist Technol. 2017 Oct;12(7):657-671. doi: 10.1080/17483107.2016.1235620. Epub 2016 Oct 20. Review.</citation>
    <PMID>27762641</PMID>
  </reference>
  <reference>
    <citation>Straudi S, Manfredini F, Lamberti N, Zamboni P, Bernardi F, Marchetti G, Pinton P, Bonora M, Secchiero P, Tisato V, Volpato S, Basaglia N. The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial. Trials. 2017 Feb 27;18(1):88. doi: 10.1186/s13063-017-1838-2.</citation>
    <PMID>28241776</PMID>
  </reference>
  <reference>
    <citation>Gandolfi M, Geroin C, Picelli A, Munari D, Waldner A, Tamburin S, Marchioretto F, Smania N. Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial. Front Hum Neurosci. 2014 May 22;8:318. doi: 10.3389/fnhum.2014.00318. eCollection 2014.</citation>
    <PMID>24904361</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rehabilitation</keyword>
  <keyword>robot assisted gait training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

